sion, and fever: Interactive risk factors for aminoglycoside and sepsis-associated acute renal failure. (1) demonstrated that strict glucose control by IIT halved the mortality of adult patients in the surgical intensive care unit (ICU) compared with the conventional glucose control regimen. Thereafter, many ICUs worldwide updated protocols to intensify glycemic control in critically ill patients. Subsequent large-scale, prospective, randomized, controlled clinical trials and metaanalyses, however, failed to find the benefit of IIT while showing increased risk for hypoglycemic episodes (2) (3) (4) (5) . A clinical trial was prematurely terminated because of a lack of evidence of efficacy and an unacceptably high rate of hypoglycemia (2). This controversy raises several pressing questions (4 -7) . Is IIT beneficial only in a select subpopulation of patients (e.g., surgical patients)? Is accurate blood glucose monitoring required to achieve the beneficial effects of IIT (given that peripheral blood samples do not always reflect systemic glycemic status, particularly in ICU patients with impaired circulation)? Is glycemic variability (i.e., a within-patient fluctuation in blood glucose levels) a more sensitive predictor of prognosis and mortality than mean blood glucose levels (8 -10) ? Is the beneficial effect of ITT in the ICU specific to patients receiving parenteral, but not enteral, nutrition? Of note, recent studies (2, 3) have reported a lower blood glucose level in controls compared with the preceding landmark study (1) . Therefore, the improved glycemic control in the control groups of recent trials may be a significant contributor to the lack of demonstrated benefit of IIT. Furthermore, hyperglycemia in the ICU can be stratified into two categories: diabetes-induced hyperglycemia and stress-induced hyperglycemia (SIH) without preexisting diabetes. Hyperglycemia, glycemic variability, and tight glucose control seem to have a greater impact on nondiabetic SIH patients than diabetic ICU patients. These new questions and conflicting data leave critical care clinicians in a quandary.
Although most of these issues await further investigations, one of the questions demands immediate attention. In the findings of the multinational Normoglycemia in the Intensive Care Evaluation-Survival Using Glucose Algorithm Regulation (NICE-SUGAR) study involving 6,104 patients, mortality was significantly increased in the IIT group (death at 90 days, 27.5% vs. 24.9% with conventional control; odds ratio, 1.14; p ϭ .02) (3). Not surprisingly, the incidence of severe hypoglycemic (blood glucose Ͻ40 mg/dL) was greater in the IIT group than in the control group (6.8% vs. 0.5%, p Ͻ .001). Hypoglycemia is a major adverse event that hampers the successful implementation of IIT. However, it is unclear whether this difference in the hypoglycemic incidence can fully account for the differences in mortality between IIT and control groups (6) . Another possibility is that exogenous insulin elicits deleterious effects, independent of glucose lowering, that increase mortality rate in the IIT group. Insulin has a number of glucoseindependent actions, including stimulation of potassium transport into the cells, sympathetic activation, sodium retention, anti-inflammatory effects, and antiapoptotic, anabolic, and mitogenic actions. These pleiotropic actions can be either protective or detrimental, dependent presumably on insulin levels and cellular context. The deleterious effects of hyperinsulinemia have been documented in disease states other than critical illness and IIT. Hyperinsulinemia is an independent risk factor for the development of atherosclerosis and ischemic heart disease. It is reasonable to speculate, therefore, that the hyperinsulinemia caused by IIT might exert deleterious effects in ICU patients, contributing to their reduced survival. The impact of hyperinsulinemia (or insulin dosage) on outcome of IIT warrants further investigation. Collectively, the accumulating evidence suggests that both hypoglycemia and the deleterious effects of hyperinsulinemia may be involved in the increased mortality observed with IIT. Therefore, one of the highest priorities in managing strict glucose control in the ICU should be to determine how to avoid severe hypoglycemia and the adverse effects of hyperinsulinemia.
The binding of insulin to its cognate receptor results in activation of multiple intracellular signaling pathways. Among others, the phosphatidylinositol 3-kinase (PI3K)-Akt/protein kinase B pathway plays a central role in insulin's actions on glucose metabolism. Insulin sensitivity is determined by hypoglycemic response to insulin, which is mainly mediated by activation of the PI3K-Akt pathway. Previous studies indicate that the PI3K-Akt pathway is specifically impaired where the insulin-resistant state is induced by obesity and trauma in rodents (11, 12) , while other signaling cascades, such as the mitogen-activated protein kinase (MAPK) pathway, are spared. Compensatory hyperinsulinemia secondary to insulin resistance promotes atherogenesis even in the absence of hyperglycemia, presumably by hyperactivation of the signaling cascades (e.g., MAPK) parallel to the PI3K-Akt pathway. In contrast, activity of the PI3K-Akt pathway is not elevated by secondary hyperinsulinemia. It is tempting to speculate, therefore, that essentially the same mechanism, hyperactivation of glucose metabolism-unrelated insulin signaling pathways, may underlie the putative detrimental effects of hyperinsulinemia in critically ill patients. Insulin resistance (impaired hypoglycemic response to insulin) plays a crucial role in SIH in critical illness, including sepsis, trauma, and major surgery. Insulin-sensitization reduces the insulin requirement to maintain euglycemia and hence helps achieve normal glucose levels with no insulin treatment or with lower dosages of insulin. In aggregate, a logical proposition is that insulin sensitization is a potential solution of the current two major issues in glycemic control in SIH: hypoglycemia and hyperinsulinemia. To date, however, this possibility has not been explored, partly because the two clinically approved insulin sensitizers, thiazolidinediones and metformin, are contraindicated in many critically ill patients owing to the adverse side effects (e.g., edema and heart failure for thiazolidinediones, lactic acidosis for metformin).
In this issue of Critical Care Medicine, Dr. Matsuda and colleagues (13) present the beneficial effects of an insulin sensitizer in a mouse model of sepsis. The authors show that inhibition of nuclear factor (NF)-B reverses glucose intolerance and ameliorates insulin resistance and hyperinsulinemia in septic mice. Importantly, the insulin sensitization was accompanied by improved survival of the animals. Sepsis-associated hyperglycemia is a common finding in the ICU. NF-B is a key transcription factor that regulates the expression of genes that play important roles in inflammation, including proinflammatory cytokines (e.g., tumor necrosis factor-␣) and inducible nitric oxide synthase. In this study, after sepsis was induced by cecal ligation and puncture (CLP), the mice were treated with the NF-B decoy oligodeoxynucleotide, which blocks the binding of NF-B to the promoter region of the downstream genes and thereby NF-B-mediated transcription. The improved insulin sensitivity and glucose tolerance by NF-B inhibition paralleled the reversal of attenuated insulin signaling, in particular the activities of the PI3K-Akt pathway in septic mice. The important role of NF-B activation in rodent models of obesity-induced insulin resistance has been established. Chronic low-grade inflammation plays an important role in obesity-induced insulin resistance (14) . Gene disruption of NF-B protects mice from obesity-induced diabetes. Furthermore, a clinical trial is underway to evaluate the efficacy and safety of an NF-B inhibitor for the treatment of type 2 diabetes. The present study clearly indicates that NF-B plays a critical role in sepsis-induced insulin resistance in mice as well. Collectively, the present findings warrant further preclinical studies to investigate the effects of insulin-sensitization on mortality in animal models of SIH, including sepsis, trauma, and major surgery.
Dr. Matsuda and colleagues' study (13) also forewarns of some potential pitfalls that should be considered in designing future studies. First, the septic mice did not exhibit overt hyperglycemia, although the animals were substantially insulin resistant and glucose intolerant. Unlike humans and rats, mice are resistant to stress-induced hyperglycemia. Thus, rats rather than mice may be a more appropriate rodent model of SIH. Other insights can be gleaned about the protective effects of the insulin sensitizer. For example, possibilities exist that not only hyperglycemic but also euglycemic ICU patients could benefit from insulin sensitization and that the blood glucose level-independent beneficial actions of insulin, which were attributed to the insulin sensitizer, might be operative in septic mice. Of note, a recent study showed that the severity of insulin resistance is associated with the severity of critical illness, although no significant association was found between insulin resistance and basal blood glucose levels (15) . Second, the impact of NF-B inhibition on survival was modest, although it was statistically significant. This could in part be explained by the absence of overt hyperglycemia and/or modest insulin sensitization in the mice, as reflected by mild amelioration of hyperinsulinemia. Alternatively, this result might be attributable to the choice of NF-B inhibitor used in this study. Anti-inflammatory strategies, such as using antagonists of tumor necrosis factor-␣, failed to show the efficacy in septic patients in clinical trials, conceivably because inflammatory responses are necessary to combat pathogenic microorganisms in critically ill patients despite the toxic effects of hyperinflammation. Furthermore, NF-B functions as a major antiapoptotic mechanism in cells. Recent studies indicate that apoptosis of immune cells or in other tissues confers increased susceptibility to infection and exacerbates organ dysfunction, which in turn lead to increased mortality in sepsis. Taken together, these findings suggest that anti-inflammatory and proapoptotic actions of NF-B inhibition might hamper the prosurvival effects of insulin sensitization in septic mice. It is worth testing the effects of insulin sensitizers other than NF-B inhibitors in rodent models of SIH. For example, Sirt1, the mammalian homolog of the yeast longevity gene, may be a potential target for improving survival in patients with SIH in the ICU. Activation of Sirt1 reverses insulin resistance in mouse models of obesity and type 2 diabetes (16) and confers stress resistance in a number of pathologic states, including neurodegeneration and heart failure (17) . A clinical trial has just been started that will test the efficacy and safety of resveratrol, a Sirt1 activator, for the treatment of patients with type 2 diabetes. Regardless of the potential pitfalls and limitations, the present study by Dr. Matsuda and colleagues (13) opens a new avenue of investigation for determining whether insulin sensitization, which targets the root problem of SIH, insulin resistance, and helps avoid severe hypoglycemia and hyperinsulinemia, is a viable alternative strategy to the current IIT for reducing mortality in ICU patients with SIH. Key questions that need to be addressed in future preclinical studies include these: What type of insulin sensitizer is more effective in promoting survival in animal models of SIH? What factors can we find that will serve as surrogate markers of the glucose-independent beneficial and adverse actions of insulin? Which conditions are the best targets of insulin sensitization: sepsis, trauma, or major surgery? Investigations of the relation between insulin dosage (and plasma insulin concentrations) and outcome of IIT in future clinical studies and post hoc analysis of previous studies should provide important and useful information on future development of glycemic care in the ICU.
